Qinprezo: Withdrawal of the marketing authorisation application
On 10 May 2017, Sunesis Europe Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for the cancer medicine Qinprezo, intended to be used in combination with cytarabine for the treatment of acute myeloid leukaemia (AML).
|International non-proprietary name (INN) or common name||
|Date of withdrawal||
|Company making the application|
Withdrawal assessment report for Qinprezo (PDF/2.36 MB)Adopted
First published: 15/08/2017
Last updated: 15/08/2017
Withdrawal letter: Qinprezo (PDF/86.08 KB)
First published: 09/06/2017
Last updated: 09/06/2017
Questions and answers on the withdrawal of the application for the marketing authorisation for Qinprezo (vosaroxin) (PDF/74.41 KB)
First published: 19/05/2017
Last updated: 19/05/2017
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter (withdrawal letter Doc. type, leave the 'Author' in properties blank).
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').